Last reviewed · How we verify
Convalescent Plasma — Competitive Intelligence Brief
phase 3
Immunoglobulin/Passive immunotherapy
Immunology/Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
Convalescent Plasma (Convalescent Plasma) — Hackensack Meridian Health. Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Convalescent Plasma TARGET | Convalescent Plasma | Hackensack Meridian Health | phase 3 | Immunoglobulin/Passive immunotherapy | ||
| Delayed administration of convalescent plasma | Delayed administration of convalescent plasma | UMC Utrecht | phase 3 | Immunoglobulin/passive immunotherapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Immunoglobulin/Passive immunotherapy class)
- Hackensack Meridian Health · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Convalescent Plasma CI watch — RSS
- Convalescent Plasma CI watch — Atom
- Convalescent Plasma CI watch — JSON
- Convalescent Plasma alone — RSS
- Whole Immunoglobulin/Passive immunotherapy class — RSS
Cite this brief
Drug Landscape (2026). Convalescent Plasma — Competitive Intelligence Brief. https://druglandscape.com/ci/convalescent-plasma. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab